CY1105082T1 - Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας - Google Patents

Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας

Info

Publication number
CY1105082T1
CY1105082T1 CY20061100957T CY061100957T CY1105082T1 CY 1105082 T1 CY1105082 T1 CY 1105082T1 CY 20061100957 T CY20061100957 T CY 20061100957T CY 061100957 T CY061100957 T CY 061100957T CY 1105082 T1 CY1105082 T1 CY 1105082T1
Authority
CY
Cyprus
Prior art keywords
treatment
flivansepin
sexual desire
desire disorders
disorders
Prior art date
Application number
CY20061100957T
Other languages
Greek (el)
English (en)
Inventor
Kenneth Robert Evans
Franco Borsini
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of CY1105082T1 publication Critical patent/CY1105082T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20061100957T 2001-10-20 2006-07-07 Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας CY1105082T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01125020 2001-10-20
PCT/EP2002/011103 WO2003035072A1 (en) 2001-10-20 2002-10-04 Use of flibanserin in the treatment of sexual disorders
EP02801880A EP1446122B1 (en) 2001-10-20 2002-10-04 Use of flibanserin in the treatment of sexual desire disorders

Publications (1)

Publication Number Publication Date
CY1105082T1 true CY1105082T1 (el) 2010-03-03

Family

ID=8179028

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100957T CY1105082T1 (el) 2001-10-20 2006-07-07 Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας

Country Status (31)

Country Link
US (9) US7151103B2 (enExample)
EP (2) EP1674102A1 (enExample)
JP (3) JP2005506370A (enExample)
KR (3) KR20090130196A (enExample)
CN (4) CN1571670A (enExample)
AR (2) AR037109A1 (enExample)
AT (1) ATE327757T1 (enExample)
AU (1) AU2002333894B2 (enExample)
BR (1) BR0213358A (enExample)
CA (1) CA2458067C (enExample)
CY (1) CY1105082T1 (enExample)
DE (1) DE60211937T2 (enExample)
DK (1) DK1446122T5 (enExample)
EA (1) EA007274B1 (enExample)
EC (1) ECSP045069A (enExample)
ES (1) ES2266632T3 (enExample)
HR (1) HRP20040352B1 (enExample)
HU (1) HUP0401023A3 (enExample)
IL (2) IL160389A0 (enExample)
ME (1) MEP42808A (enExample)
MX (1) MXPA04003666A (enExample)
MY (1) MY127290A (enExample)
NO (1) NO325556B1 (enExample)
NZ (1) NZ532079A (enExample)
PL (1) PL208744B1 (enExample)
PT (1) PT1446122E (enExample)
RS (1) RS50876B (enExample)
SI (1) SI1446122T1 (enExample)
UA (1) UA78974C2 (enExample)
WO (1) WO2003035072A1 (enExample)
ZA (1) ZA200401366B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CA2532252A1 (en) * 2003-07-16 2005-01-27 Pfizer Inc. Treatment of sexual dysfunction
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
EP1715921B1 (en) 2003-09-25 2013-04-24 Abraxis BioScience, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
NZ551356A (en) 2004-05-11 2009-09-25 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
US20060199805A1 (en) * 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1858516A1 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2009500440A (ja) * 2005-07-12 2009-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性欲障害治療用医薬組成物
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CA2657045A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2056797A2 (en) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH Controlled release system and method for manufacturing the same
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
US8304601B2 (en) * 2007-01-23 2012-11-06 Keiko Fujikawa Mouse model for eye disease
JP2010522714A (ja) * 2007-03-28 2010-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な医薬組成物
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
DE102011012712A1 (de) 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
HK1211239A1 (en) * 2012-08-06 2016-05-20 S1 Biopharma, Inc. Treatment regimens
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US479739A (en) * 1892-07-26 dimond
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) * 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
FI791926A7 (fi) 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3620643A1 (de) 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
GB8601160D0 (en) 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
AU8629691A (en) 1990-08-09 1992-03-02 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
CA2071488C (en) 1990-08-24 1996-05-07 Kazuto Kobayashi Base for film-coating pharmaceuticals and method for preparing same
NZ241613A (en) 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
FR2675800A1 (fr) 1991-04-26 1992-10-30 Rhone Poulenc Rorer Sa Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
FI934894L (fi) 1991-05-07 1993-11-05 Merck & Co Inc Fibrinogenreceptorantagonister
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE4216364A1 (de) 1991-12-14 1993-11-25 Thomae Gmbh Dr K Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5225417A (en) 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
FR2707294B1 (fr) 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE69523155T2 (de) 1994-06-14 2002-02-07 Pfizer Inc., New York Benzimidazolonderivate mit zentraler dopaminerger aktivität
AU699224B2 (en) 1994-08-23 1998-11-26 Smithkline Beecham Plc Improved pharmaceutical formulations containing ibuprofen and codeine
ES2204932T3 (es) 1994-09-12 2004-05-01 Eli Lilly And Company Limited Moduladores serotonergicos.
JPH08143476A (ja) 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
GB9613423D0 (en) 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
AU5179898A (en) 1996-11-06 1998-05-29 Sharmatek, Inc. Delayed delivery system for acid-sensitive drugs
JP2001504851A (ja) 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのnk−1受容体拮抗薬の使用
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US20040023948A1 (en) 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
ES2226128T3 (es) 1997-06-11 2005-03-16 THE PROCTER & GAMBLE COMPANY Comprimido revestido con una pelicula para una seguridad del tracto gastrointestinal superior mejorada.
EP0901787B1 (en) 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
CH692199A8 (fr) 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
AU4068599A (en) 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
EP1077704A4 (en) 1998-05-21 2002-01-30 Lilly Co Eli COMBINATION THERAPY FOR TREATING DEPRESSION
US20020151543A1 (en) 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
EP1085869A4 (en) 1998-06-11 2001-10-04 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
US6068846A (en) 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
AU1738900A (en) * 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
JP2002542287A (ja) 1999-04-28 2002-12-10 レスピラトリウス アクチボラゲット 医 薬
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
DE19961334A1 (de) 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
CN1660435A (zh) 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
KR20030017571A (ko) 2000-06-28 2003-03-03 화이자 프로덕츠 인크. 멜라노코르틴 수용체 리간드
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
AU2002223528A1 (en) 2000-09-19 2002-04-02 Boeringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
AU2001293804A1 (en) 2000-09-19 2002-04-02 Boehringer Ingelheim Pharma Kg New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
WO2002041894A2 (en) 2000-11-22 2002-05-30 Abbott Laboratories Selective dopamine d4 receptor agonists for treating sexual dysfunction
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
HRP20030751A2 (en) 2001-03-28 2005-08-31 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
ES2267627T3 (es) 2001-05-11 2007-03-16 Jurgen K. Dr. Beck Flibaserina para el tratamiento de los trastornos del movimiento estrapiramidal.
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
ATE411021T1 (de) 2001-07-18 2008-10-15 Merck & Co Inc Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
DE60223031T2 (de) 2001-07-30 2008-07-24 Spectrum Pharmaceuticals, Inc., Irvine Arylpiperazin gebundene tetrahydroindolonderivate
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DK1414816T3 (da) 2001-08-02 2005-04-11 Bidachem Spa Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling
US20030060475A1 (en) 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10138273A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
HRP20041092B1 (hr) 2002-05-22 2013-05-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novi farmaceutski pripravci flibanserina
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
GB0225908D0 (en) 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20040132697A1 (en) 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040193452A1 (en) 2003-01-06 2004-09-30 Laura Berman Method and system for computerized sexual function assessment of female users
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
CA2532252A1 (en) 2003-07-16 2005-01-27 Pfizer Inc. Treatment of sexual dysfunction
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
EP1510133A1 (en) * 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005044238A1 (en) 2003-11-07 2005-05-19 Ranbaxy Laboratories Limited Modified release solid dosage form of amphetamine salts
US20050239798A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20060014757A1 (en) 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
JP2008516909A (ja) 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−3アゴニストの使用
EP1858516A1 (en) 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
US20060199805A1 (en) 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1904182A2 (en) 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
JP2008540672A (ja) 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
CA2608363A1 (en) 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
TW200715774A (en) 2005-08-16 2007-04-16 Wionics Research Packet detection
HU227490B1 (en) 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
JP2009510099A (ja) 2005-09-30 2009-03-12 スミスクライン・ビーチャム・コーポレイション 医薬組成物
US20070123540A1 (en) 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2387994A1 (en) 2006-01-27 2011-11-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
EP1988898A2 (en) 2006-02-18 2008-11-12 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
EP1988897A1 (en) 2006-02-20 2008-11-12 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of urinary incontinence
EP1991228A1 (en) 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Treatment of prevention of valvular heart disease with flibanserin
JP2009536176A (ja) 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CA2657045A1 (en) 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP2056797A2 (en) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH Controlled release system and method for manufacturing the same
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
JP2010522714A (ja) 2007-03-28 2010-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な医薬組成物
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts

Also Published As

Publication number Publication date
NZ532079A (en) 2007-03-30
US20140057923A1 (en) 2014-02-27
KR101235102B1 (ko) 2013-02-20
EP1446122A1 (en) 2004-08-18
CA2458067A1 (en) 2003-05-01
CN1571670A (zh) 2005-01-26
NO325556B1 (no) 2008-06-16
EP1674102A1 (en) 2006-06-28
US10098876B2 (en) 2018-10-16
AR077480A2 (es) 2011-08-31
CN101347431A (zh) 2009-01-21
ATE327757T1 (de) 2006-06-15
PL208744B1 (pl) 2011-06-30
US20150011563A1 (en) 2015-01-08
MY127290A (en) 2006-11-30
US7151103B2 (en) 2006-12-19
PT1446122E (pt) 2006-08-31
ZA200401366B (en) 2005-01-26
US9468639B2 (en) 2016-10-18
MEP42808A (en) 2011-05-10
NO20041588L (no) 2004-04-19
DE60211937T2 (de) 2006-12-28
DK1446122T3 (da) 2006-07-03
KR20110132479A (ko) 2011-12-07
US8227471B2 (en) 2012-07-24
HUP0401023A3 (en) 2004-10-28
HUP0401023A2 (hu) 2004-08-30
AU2002333894B2 (en) 2007-11-01
US20190000842A1 (en) 2019-01-03
JP2007131631A (ja) 2007-05-31
US20180055839A1 (en) 2018-03-01
US20150342948A1 (en) 2015-12-03
YU30004A (sh) 2006-08-17
US20030104980A1 (en) 2003-06-05
UA78974C2 (en) 2007-05-10
AR037109A1 (es) 2004-10-20
IL160389A (en) 2010-05-31
MXPA04003666A (es) 2004-07-22
HRP20040352B1 (en) 2012-02-29
JP2012067134A (ja) 2012-04-05
CA2458067C (en) 2009-02-10
US20070072872A1 (en) 2007-03-29
PL367358A1 (en) 2005-02-21
WO2003035072A1 (en) 2003-05-01
IL160389A0 (en) 2004-07-25
JP2005506370A (ja) 2005-03-03
EA007274B1 (ru) 2006-08-25
KR20040047931A (ko) 2004-06-05
EA200400481A1 (ru) 2004-10-28
CN102125557A (zh) 2011-07-20
US20170100392A1 (en) 2017-04-13
ECSP045069A (es) 2004-05-28
BR0213358A (pt) 2004-10-26
CN102058597A (zh) 2011-05-18
US20130096137A1 (en) 2013-04-18
EP1446122B1 (en) 2006-05-31
HRP20040352A2 (en) 2005-02-28
RS50876B (sr) 2010-08-31
DK1446122T5 (da) 2006-08-14
ES2266632T3 (es) 2007-03-01
SI1446122T1 (sl) 2006-10-31
KR20090130196A (ko) 2009-12-18
US10307420B2 (en) 2019-06-04
DE60211937D1 (de) 2006-07-06
US9782403B2 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
DOP2002000429A (es) Imidazotriazinas
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
CY1108191T1 (el) Χρηση λεβοκετιρισινης για την θεραπεια επιμονης αλλεργικης ρινιτιδας
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
GB0222282D0 (en) Therapeutic device for the treatment of symptons caused by diseases
UA51372A (uk) Засіб для лікування гнійного гаймориту
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.
ITMI20020055A0 (it) Composizione medicinale per il trattamento della degenerazione artilaginea
ITMI20031273A1 (it) Composizioni a base di cenere di vegetali per la terapia di affezioni cutanee.